ArticleCell host & microbe2018
Characterization of BK Polyomaviruses from Kidney Transplant Recipients Suggests a Role for APOBEC3 in Driving In-Host Virus Evolution.
Article in Cell host & microbe, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 81 citations in OpenAlex.
- Review
- Herpes simplex virus type 1 R-loops are targets for APOBEC-mediated mutagenesis.Genome biology · 2026Article
- Broadly neutralizing human monoclonal antibodies against BK polyomavirus genotypes.The Journal of general virology · 2025Article
- ISG20 RestrictsMicroorganisms · 2025Article
- Article
- CRISPR-based assays for the detection of BK virus and JC virus infections post-kidney transplantation.Military Medical Research · 2025Article
- Tumor Necrosis Factor-Alpha Inhibits the Replication of Patient-Derived Archetype BK Polyomavirus While Activating Rearranged Strains.Journal of medical virology · 2025Article
- Susceptibility to BK polyomavirus-associated hemorrhagic cystitis in children undergoing allogeneic transplant.Haematologica · 2025Article
- Neutralizing Antibodies Targeting BK Polyomavirus: Clinical Importance and Therapeutic Potential for Kidney Transplant Recipients.Journal of the American Society of Nephrology : JASN · 2024Review
- Genomic Landscape and Regulation of RNA Editing in Pekin Ducks Susceptible to Duck Hepatitis A Virus Genotype 3 Infection.International journal of molecular sciences · 2024Article
- Article
- The Intricate Interplay between APOBEC3 Proteins and DNA Tumour Viruses.Pathogens (Basel, Switzerland) · 2024Review
- Dual roles of BK Polyomavirus in promoting urothelial carcinoma progression via regulating CLDN1.Biomarker research · 2024Article
- BK Polyomavirus Diversity After Hematopoietic Stem Cell Transplantation.The Journal of infectious diseases · 2023Article
- Polyomavirus Wakes Up and Chooses Neurovirulence.Viruses · 2023Review
- Time-dependent variations in BK polyomavirus genome from kidney transplant recipients with persistent viremia.Scientific reports · 2023Article
- A cluster of broadly neutralizing IgG against BK polyomavirus in a repertoire dominated by IgM.Life science alliance · 2023Article
- Evidence for virus-mediated oncogenesis in bladder cancers arising in solid organ transplant recipients.eLife · 2023Article
- A multivalent polyomavirus vaccine elicits durable neutralizing antibody responses in macaques.Vaccine · 2023Article
- The APOBEC3B cytidine deaminase is an adenovirus restriction factor.PLoS pathogens · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 5 institutions in 2 countries.
Funding
Abstract
BK polyomavirus (BKV) frequently causes nephropathy (BKVN) in kidney transplant recipients (KTRs). BKV has also been implicated in the etiology of bladder and kidney cancers. We characterized BKV variants from two KTRs who developed BKVN followed by renal carcinoma. Both patients showed a swarm of BKV sequence variants encoding non-silent mutations in surface loops of the viral major capsid protein. The temporal appearance and disappearance of these mutations highlights the intra-patient evolution of BKV. Some of the observed mutations conferred resistance to antibody-mediated neutralization. The mutations also modified the spectrum of receptor glycans engaged by BKV during host cell entry. Intriguingly, all observed mutations were consistent with DNA damage caused by antiviral APOBEC3 cytosine deaminases. Moreover, APOBEC3 expression was evident upon immunohistochemical analysis of renal biopsies from KTRs. These results provide a snapshot of in-host BKV evolution and suggest that APOBEC3 may drive BKV mutagenesis in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.